Intravenous Iron Therapy for Severe Iron Deficiency

Indications and Advantages

The American College of Cardiology suggests that oral iron absorption is limited and often insufficient in patients with chronic blood loss, making intravenous iron a superior option 1
The European Crohn's and Colitis Organisation recommends that unabsorbed oral iron can cause significant gastrointestinal side effects, which can be avoided with intravenous iron therapy 2, 3
Intravenous iron achieves more rapid and complete iron repletion compared to oral formulations, as supported by the American College of Gastroenterology 3, 1
The American College of Cardiology recommends that ferric carboxymaltose can deliver up to 1000 mg (or 20 mg/kg, whichever is lower) in a single 15-minute infusion, without requiring a test dose 1, 2

The European Society for Medical Oncology suggests monitoring for hypophosphatemia, particularly with repeated dosing of ferric carboxymaltose, and following up hemoglobin every 4 weeks until normalized, then every 3 months for the first year 2, 3
The American College of Cardiology recommends initiating re-treatment when ferritin drops below 100 ng/mL or hemoglobin falls below normal range (12 g/dL for women, 13 g/dL for men) 3

Standard criteria for iron deficiency anemia diagnosis typically requires serum ferritin less than 30 ng/mL or a transferrin saturation less than 20% 4

IV iron therapy is indicated when there is documented iron deficiency with unsatisfactory response to oral iron, rapid blood loss exceeding oral iron replacement capacity, gastrointestinal disorders that may be aggravated by oral iron, poor compliance with oral iron therapy, or malabsorption conditions 5

Ferric carboxymaltose has been associated with hypophosphatemia, particularly with repeated dosing 5
Monitor for adverse effects for at least 30 minutes following IV administration 6
Avoid early re-evaluation of iron status (within 4 weeks of IV iron administration) as ferritin levels increase markedly following administration 6